- Home
- ROIV vs ENTG Comparison
ROIV vs ENTG Comparison
Compare ROIV & ENTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | ENTG |
|---|---|---|
| Founded | 2014 | 1966 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Plastic Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 25.5B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ROIV | ENTG |
|---|---|---|
| Price | $36.89 | $152.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $50.00 | ★ $187.64 |
| AVG Volume (30 Days) | ★ 6.2M | 2.5M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.24 |
| Revenue | $8,260,000.00 | ★ $3,196,600,000.00 |
| Revenue This Year | $593.33 | $15.63 |
| Revenue Next Year | $648.48 | $14.88 |
| P/E Ratio | ★ N/A | $132.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.30 | $67.97 |
| 52 Week High | $42.50 | $186.94 |
Technical Indicators
Market Signals| Indicator | ROIV | ENTG |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 51.84 |
| Support Level | $33.11 | $127.01 |
| Resistance Level | $37.89 | $162.77 |
| Average True Range (ATR) | 1.25 | 8.37 |
| MACD | 0.32 | 0.58 |
| Stochastic Oscillator | 70.31 | 58.72 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ENTG Entegris Inc.
Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.